Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Aimmune Therapeutics, Inc. | aimt-ex322_10.htm |
| EX-31.2 - EX-31.2 - Aimmune Therapeutics, Inc. | aimt-ex312_9.htm |
| EX-31.1 - EX-31.1 - Aimmune Therapeutics, Inc. | aimt-ex311_12.htm |
| EX-23.1 - EX-23.1 - Aimmune Therapeutics, Inc. | aimt-ex231_11.htm |
| EX-10.5(B) - EX-10.5(B) - Aimmune Therapeutics, Inc. | aimt-ex105b_1498.htm |
| EX-10.5(A) - EX-10.5(A) - Aimmune Therapeutics, Inc. | aimt-ex105a_713.htm |
| EX-4.5 - EX-4.5 - Aimmune Therapeutics, Inc. | aimt-ex45_711.htm |
| EX-4.4 - EX-4.4 - Aimmune Therapeutics, Inc. | aimt-ex44_712.htm |
| 10-K - 10-K - Aimmune Therapeutics, Inc. | aimt-10k_20161231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Aimmune Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: March 15, 2017 |
|
By: |
/s/ Stephen G. Dilly |
|
|
|
|
Stephen G. Dilly, M.B.B.S., PhD. |
|
|
|
|
President, Chief Executive Officer and Director (Principal Executive Officer) |